APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liraglutide Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liraglutide Drugs Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchLiraglutide Drugs Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Liraglutide Drugs Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Liraglutide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liraglutide Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Liraglutide Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Liraglutide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liraglutide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liraglutide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liraglutide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liraglutide Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liraglutide Drugs market include Novo Nordisk and Viatris among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Liraglutide Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liraglutide Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liraglutide Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Liraglutide Drugs market.

Liraglutide Drugs Segment by Company

Novo Nordisk

Viatris

Liraglutide Drugs Segment by Type

Victoza

Saxenda

Liraglutide Drugs Segment by Application

Type 2 Diabetes

Obesity

Liraglutide Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Liraglutide Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Liraglutide Drugs key companies, revenue, market share, and recent developments.

3. To split the Liraglutide Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Liraglutide Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liraglutide Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Liraglutide Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liraglutide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liraglutide Drugs industry.

Chapter 3: Detailed analysis of Liraglutide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Liraglutide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Liraglutide Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liraglutide Drugs Industry Trends Table 2. Liraglutide Drugs Industry Drivers Table 3. Liraglutide Drugs Industry Opportunities and Challenges Table 4. Liraglutide Drugs Industry Restraints Table 5. Global Liraglutide Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liraglutide Drugs Revenue Share by Company (2021-2026) Table 7. Global Liraglutide Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Liraglutide Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Liraglutide Drugs Company, Product Type & Application Table 10. Global Liraglutide Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Liraglutide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Victoza Table 15. Significant Companies of Saxenda Table 16. Global Liraglutide Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Liraglutide Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Liraglutide Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Liraglutide Drugs Sales Value Share by Type (2021-2026) Table 20. Global Liraglutide Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Type 2 Diabetes Table 22. Significant Companies of Obesity Table 23. Global Liraglutide Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Liraglutide Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Liraglutide Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Liraglutide Drugs Sales Value Share by Application (2021-2026) Table 27. Global Liraglutide Drugs Sales Value Share by Application (2027-2032) Table 28. Global Liraglutide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Liraglutide Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Liraglutide Drugs Sales Value Share by Region (2021-2026) Table 31. Global Liraglutide Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Liraglutide Drugs Sales Value Share by Region (2027-2032) Table 33. Global Liraglutide Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Liraglutide Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Liraglutide Drugs Sales Value Market Share by Country (2021-2026) Table 36. Global Liraglutide Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Liraglutide Drugs Sales Value Market Share by Country (2027-2032) Table 38. Novo Nordisk Company Information Table 39. Novo Nordisk Business Overview Table 40. Novo Nordisk Liraglutide Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Novo Nordisk Liraglutide Drugs Product Portfolio Table 42. Novo Nordisk Recent Development Table 43. Viatris Company Information Table 44. Viatris Business Overview Table 45. Viatris Liraglutide Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Viatris Liraglutide Drugs Product Portfolio Table 47. Viatris Recent Development Table 48. Research Programs/Design for This Report Table 49. Authors List of This Report Table 50. Secondary Sources Table 51. Primary Sources List of Figures Figure 1. Liraglutide Drugs Product Image Figure 2. Global Liraglutide Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liraglutide Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Liraglutide Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Victoza Image Figure 8. Saxenda Image Figure 9. Global Liraglutide Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Liraglutide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Liraglutide Drugs Sales Value Share by Type (2021-2032) Figure 12. Type 2 Diabetes Image Figure 13. Obesity Image Figure 14. Global Liraglutide Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liraglutide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liraglutide Drugs Sales Value Share by Application (2021-2032) Figure 17. Global Liraglutide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Liraglutide Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Liraglutide Drugs Sales Value (2021-2032) & (US$ Million) Figure 20. North America Liraglutide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Liraglutide Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Liraglutide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Liraglutide Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Liraglutide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Liraglutide Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. South America Liraglutide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Liraglutide Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Liraglutide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Liraglutide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Victoza
  • Saxenda
Applications
  • Type 2 Diabetes
  • Obesity
Companies covered
  • Novo Nordisk
  • Viatris

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Liraglutide Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Liraglutide Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Liraglutide Drugs Market Dynamics
  1. 2.1 Liraglutide Drugs Industry Trends
  2. 2.2 Liraglutide Drugs Industry Drivers
  3. 2.3 Liraglutide Drugs Industry Opportunities and Challenges
  4. 2.4 Liraglutide Drugs Industry Restraints
3 Liraglutide Drugs Market by Company
  1. 3.1 Global Liraglutide Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Liraglutide Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Liraglutide Drugs Company Ranking (2024-2026)
  4. 3.4 Global Liraglutide Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Liraglutide Drugs Company Product Type and Application
  6. 3.6 Global Liraglutide Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Liraglutide Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Liraglutide Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Liraglutide Drugs Market by Type
  1. 4.1 Liraglutide Drugs Type Introduction
  2. 4.1.1 Victoza
  3. 4.1.2 Saxenda
  4. 4.2 Global Liraglutide Drugs Sales Value by Type
  5. 4.2.1 Global Liraglutide Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liraglutide Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Liraglutide Drugs Sales Value Share by Type (2021-2032)
5 Liraglutide Drugs Market by Application
  1. 5.1 Liraglutide Drugs Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Obesity
  4. 5.2 Global Liraglutide Drugs Sales Value by Application
  5. 5.2.1 Global Liraglutide Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Liraglutide Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Liraglutide Drugs Sales Value Share by Application (2021-2032)
6 Liraglutide Drugs Regional Value Analysis
  1. 6.1 Global Liraglutide Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liraglutide Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Liraglutide Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Liraglutide Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Liraglutide Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Liraglutide Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Liraglutide Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Liraglutide Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Liraglutide Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Liraglutide Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Liraglutide Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Liraglutide Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Liraglutide Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Liraglutide Drugs Sales Value Share by Country, 2025 VS 2032
7 Liraglutide Drugs Country-level Value Analysis
  1. 7.1 Global Liraglutide Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liraglutide Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Liraglutide Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Liraglutide Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Liraglutide Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Liraglutide Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Liraglutide Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk Liraglutide Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk Liraglutide Drugs Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 Viatris
  8. 8.2.1 Viatris Company Information
  9. 8.2.2 Viatris Business Overview
  10. 8.2.3 Viatris Liraglutide Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Viatris Liraglutide Drugs Product Portfolio
  12. 8.2.5 Viatris Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst